ERYCETTE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erycette, and what generic alternatives are available?
Erycette is a drug marketed by Johnson And Johnson and is included in one NDA.
The generic ingredient in ERYCETTE is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erycette
A generic version of ERYCETTE was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYCETTE?
- What are the global sales for ERYCETTE?
- What is Average Wholesale Price for ERYCETTE?
Summary for ERYCETTE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 4,157 |
| DailyMed Link: | ERYCETTE at DailyMed |
US Patents and Regulatory Information for ERYCETTE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Johnson And Johnson | ERYCETTE | erythromycin | SWAB;TOPICAL | 050594-001 | Feb 15, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
